Meta-analysis of Randomized Controlled Trials Assessing the Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies on Mortality and Cardiovascular Outcomes
- 1 December 2019
- journal article
- research article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 124 (12) , 1869-1875
Abstract
No abstract availableKeywords
Funding Information
- AstraZeneca
- Sanofi
- Amgen
- Servier
This publication has 23 references indexed in Scilit:
- Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trialJournal of Clinical Lipidology, 2015
- Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized TrialThe Journal of Clinical Endocrinology & Metabolism, 2015
- Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With HypercholesterolemiaAnnals of Internal Medicine, 2015
- Ezetimibe Added to Statin Therapy after Acute Coronary SyndromesNew England Journal of Medicine, 2015
- Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I studyAmerican Heart Journal, 2015
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular EventsNew England Journal of Medicine, 2015
- Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular EventsNew England Journal of Medicine, 2015
- 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in AdultsJACC, 2014
- A 52-Week Placebo-Controlled Trial of Evolocumab in HyperlipidemiaNew England Journal of Medicine, 2014
- Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary SyndromesNew England Journal of Medicine, 2004